Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C

Hepatitis C virus (HCV) is estimated to affect up to 150 million people worldwide. Despite worldwide prevalence, treatment modalities prior to 2011 remained suboptimal, with low virologic response rates and intolerable side effect profiles. Fortunately, the landscape of treatment for chronic hepatit...

Descripción completa

Detalles Bibliográficos
Autores principales: Bell, Allison M., Wagner, Jamie L., Barber, Katie E., Stover, Kayla R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925941/
https://www.ncbi.nlm.nih.gov/pubmed/27403342
http://dx.doi.org/10.1155/2016/3852126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925941/
https://www.ncbi.nlm.nih.gov/pubmed/27403342
http://dx.doi.org/10.1155/2016/3852126

Ejemplares similares